Precision biotechnology for your protocol
Research peptides for sale in Panama: 39 compounds organized into 6 therapeutic series. BPC-157, TB-500, Retatrutide, NAD+, Semax, Selank, Epithalon, MOTS-C, PT-141, and more. Complete guide to reconstitution, protocols, and peptide cycles.
How we understand peptides
We don't sell pills: we offer a precise biotechnology system organized by clinical objectives. Three pillars that shape every decision.
The 6 Nexura Series
Each series groups peptides by biological objective. Identify your goal and find the system designed for it.
Complete peptide catalog
39 peptides + reconstitution solvents with a complete technical sheet: mechanism of action, dose, frequency, and key benefits.
Frequencies and cycles by peptide
Application reference guide for the 39 peptides in the Nexura catalog. For dose and reconstitution calculations, use the Calculator.
| Peptide | Series | Frequency | Cycle duration | Minimum rest | Schedule | Key precaution |
|---|---|---|---|---|---|---|
| Retatrutide | Metabolic | 1× weekly | 3 months Titration: +2 mg every 4 wks up to 12 mg |
1 month | As Preferred | Hypoglycemia, pancreatic, renal, and GI conditions |
| Tirzepatida | Metabolic | 1× weekly | 3 months | 1 month | As Preferred | Hypoglycemia, pancreatic, renal, and GI conditions |
| 5-Amino-1MQ | Metabolic | Daily | 4–8 weeks Up to 12–16 wks in advanced protocols |
4–8 weeks | Morning | Alters energy metabolism and cellular methylation; requires a complete washout |
| Tesamorelin + Ipamorelin | Metabolic | 1× daily 7 days or 5+2 schedule |
8–12 weeks Max. 16 weeks |
4–8 weeks | Evening or Morning | Strict fast for 2 h before; no food for 30–60 min after |
| Eloralintide | Metabolic | 1× weekly Escalate 3 → 6 → 9 mg every 4 weeks |
Up to 48 weeks | No established schedule | Same day each week | Nausea and fatigue, more common with high starting doses: escalate gradually. Avoid with a history of pancreatitis |
| MOTS-C | Longevity | 1–7× weekly | 1–4 months Adjust based on response |
1 month | Morning | Tachycardia, insomnia (uncommon) |
| NAD+ | Longevity | 1–3× weekly | 1–4 months | 1 month | Morning | Nausea, flushing; caution with anticoagulants and B3/B6 |
| Epithalon | Longevity | Daily (during the cycle) | Year 1: Month 1 daily → months 2–3: 10–20 d/month → months 4–12 off Year 2+: 10–20-day cycles, 3× per year |
See cycle structure ① | Evening | Fatigue, headache; generally well tolerated |
| GHK-Cu | Longevity | Daily | 6 weeks Up to 3–4 cycles per year |
30 days | As Preferred | Burning at the injection site; caution with autoimmune diseases |
| SS-31 | Longevity | Daily | 10–30 days | 30 days | Morning | Headache, GI discomfort; caution with renal/hepatic conditions |
| AHK-Cu | Longevity | Daily | 6 weeks Up to 3–4 cycles per year |
30 days | As Preferred | Copper tripeptide; burning at the injection site |
| Glutathione | Longevity | 1–3× per week Lower dose = more frequent |
~1-month cycles Extendable to 3–4 months |
1 month | Morning, fasted | Nausea and GI discomfort at high doses; caution with asthma or sulfur allergy; stop 2 weeks before surgery |
| Thymalin | Longevity | Daily (short course) | 10–20 consecutive days Only 1–2 courses per year |
6 months | Morning | Short, intensive course; not designed for prolonged use |
| FOXO4-DRI | Longevity | Every other day or 3 consecutive days |
3–7 days maximum Pulse protocol |
3–6 months | Morning, deeply fasted | Pulse senolytic: never use in continuous or prolonged cycles |
| Humanin | Longevity | 3× weekly Start at 0.5 mg; 1 mg is typical |
4–8 weeks | 2–4 weeks | Morning | Mild injection-site reaction and fatigue. Contraindicated with active cancer (anti-apoptotic effect) |
| BPC-157 | Recovery | Daily | 12 weeks (progressive titration) Wk 1–2 → Wk 3–4 → Wk 5–6 → Wk 7–12 |
— | Morning | Generally well tolerated |
| TB-500 | Recovery | Daily | 30–90 days | 30 days | As Preferred | Contraindicated in active autoimmune disorders or active cancer |
| KPV | Recovery | Daily | 30–120 days | 30 days | As Preferred | Headache, nausea; generally well tolerated |
| BPC-157 + TB-500 | Recovery | 3× per week | 30–90 days | 30 days | As Preferred | Generally well tolerated |
| Thymosin Alpha-1 | Recovery | 2× per week E.g., Monday and Thursday |
4–8 weeks Up to 24 wks in prolonged modulation |
30–60 days | Morning | Immune modulator: always keep the same time of day for each application |
| LL-37 | Recovery | 3–5× per week or once daily |
4–8 weeks Max. 12 weeks |
4 weeks | 6:00–9:00 AM, fasted | Avoid prolonged immune overstimulation |
| VIP | Recovery | Daily, in cycles ③ | 10–20-day cycles Year 1 month 1: continuous daily |
~4 months (Year 2+) | Fasted / away from meals | Affects GI motility and digestive secretions; a cyclical, not continuous, bioregulator |
| GLOW | Recovery | 1× daily or 5 days on + 2 days off |
4–8 weeks Typical: 2.33 mg × 4 weeks · max. 12 wks |
2–4 weeks | Same time each day | Blend of GHK-Cu, BPC-157, and TB-500; reconstituting with 3 mL yields ~23.3 mg/mL |
| KLOW | Recovery | 1× daily or 5 days on + 2 days off |
8–12 weeks Max. 16 weeks |
2–4 weeks | Same time each day | Standard dose 2.67 mg; always administer at the same time of day for stable levels |
| Semax | Neuro | 1–7× weekly | 6 weeks | 6 weeks | Morning | Headache, anxiety; caution with antidepressants/antipsychotics |
| Selank | Neuro | 1–7× weekly | 6 weeks | 6 weeks | Morning | Headache, anxiety; caution with antidepressants/antipsychotics |
| PE-22-28 | Neuro | Daily | 30 days | 30 days | Morning | Headache, fatigue; caution with antidepressants/antipsychotics |
| DSIP | Neuro | Start: daily (~3 h before bed) Maintenance: 1× weekly as needed |
Until sleep pattern stabilizes | — | Night | Contraindicated in active cancer or hormonal imbalances |
| ADAMAX | Neuro | 1× daily | 4–8 weeks Short cycles to avoid tolerance |
2–4 weeks | First thing AM | Highly stimulating: administering it in the afternoon or evening can cause severe insomnia. Once reconstituted: use within 1–2 weeks at 2–8 °C |
| Oxytocin | Neuro | Daily or several times per week |
Weeks to months | Pause at the end of each cycle | Before the event | SubQ or intranasal route; with modified versions (acetate/amidate), start with a more conservative schedule |
| P-21 | Neuro | Daily Start at 100 mcg; increase to 300–500 mcg |
4–8 weeks | 4 weeks | Morning | Transient headache or brain fog at first; late-day doses can disrupt sleep |
| Tesamorelin | Performance | 1–7× weekly 30 min before eating or 2 h after |
8–12 weeks | 4–8 weeks | Evening | Water retention, headache; contraindicated in hormone-sensitive cancers |
| CJC-1295 | Performance | Daily or 1–2 large doses/week Can be combined with Ipamorelin for GH synergy |
6–8 weeks | 4–8 weeks | Evening | Water retention; contraindicated in hormone-sensitive cancers |
| Ipamorelin | Performance | Daily (7× weekly) Multiple doses/day possible for greater GH secretion |
8–12 weeks | 4–8 weeks | As Preferred | Contraindicated in hormone-sensitive cancers; history of severe hypoglycemia |
| CJC-1295 + Ipamorelin | Performance | 2–3× per week | 8–12 weeks | 4–8 weeks | Evening | Administer on an empty stomach so as not to block the natural GH pulse |
| ACE-031 | Performance | 1–2 days per week Half-life 3–5 days |
4–6 weeks Max. 8 weeks |
4–8 weeks | As Preferred | Prolonged use increases vascular risk (epistaxis) and generates antibodies that nullify its effect |
| IGF-1 LR3 | Performance | Daily or training days only |
4–6 weeks Max. 8 weeks |
4–6 weeks | Pre- or post-workout | Never fasted: it acts like insulin. Consume carbohydrates to prevent hypoglycemia |
| PT-141 | Performance+ | Max. 1 dose every 72 h Administer 45–60 min before; effect lasts 24–72 h |
As needed | Min. 72 h between doses | As Preferred | Do not combine with PDE-5 inhibitors; cardiovascular caution |
| Kisspeptin-10 | Performance+ | 2–3× per week Sustained over several months |
Several months | 1 month | Morning | In women, it is cycled during the follicular phase before ovulation and discontinued afterward |
Series side by side
Compare the benefits, primary use, and duration of each series to make an informed decision.
Principles of safe administration
Peptides are powerful tools. Their responsible use depends on four non-negotiable principles.
Essential technical terms
18 abbreviations and scientific terms found in the peptide literature.
- RUO — Research Use Only
- Products exclusively for scientific research. Not approved for human or veterinary use.
- COA — Certificate of Analysis
- Document certifying the purity, identity, and composition of a lot, usually via HPLC and spectrometry.
- HPLC — High-Performance Liquid Chromatography
- Analytical technique that separates, identifies, and quantifies the components of a sample. The standard for verifying peptide purity.
- SubQ — Subcutaneous
- Route of administration under the skin, into the fatty tissue. The most common route for research peptides.
- IM — Intramuscular
- Route of administration into muscle tissue. Faster absorption than SubQ.
- IV — Intravenous
- Route of administration directly into the bloodstream. Immediate bioavailability.
- IN — Intranasal
- Administration through the nasal mucosa. Useful for peptides that cross the blood–brain barrier (Semax, Selank).
- IU — International Unit / Insulin Unit
- Standardized unit of measurement. On insulin syringes: 100 IU = 1 mL on a U-100 syringe.
- GH — Growth Hormone
- Growth hormone. Produced by the pituitary gland, it regulates growth, metabolism, and body composition.
- GHRH — Growth Hormone Releasing Hormone
- Hormone that stimulates the release of GH from the pituitary gland. Tesamorelin and CJC-1295 are GHRH analogs.
- IGF-1 — Insulin-like Growth Factor 1
- Hormone that mediates the effects of GH. Clinical marker for evaluating the somatotropic axis.
- GLP-1 — Glucagon-Like Peptide 1
- Gut hormone that regulates glucose and appetite. Retatrutide is a triple agonist that includes GLP-1.
- BDNF — Brain-Derived Neurotrophic Factor
- Growth factor that promotes neuronal survival and plasticity. PE-22-28 acts as its analog.
- ACTH — Adrenocorticotropic Hormone
- Hormone that regulates the stress response. Semax is a synthetic fragment of ACTH (4-10).
- BAC — Bacteriostatic Water
- Sterile water with 0.9% benzyl alcohol. Standard solvent for reconstituting lyophilized peptides.
- mcg / µg — Microgram
- 1 microgram = 0.001 milligrams. Common unit for peptide doses (1 mg = 1000 mcg).
- Lyophilized — Powder dehydrated by sublimation
- The form in which peptides are supplied for preservation. Requires reconstitution with BAC before use.
- PK / PD — Pharmacokinetics / Pharmacodynamics
- PK: how a compound is absorbed, distributed, and eliminated. PD: what effect it produces. Together they determine the optimal dose and frequency.
About Nexura Bio Systems
Specialized supplier of research peptides (RUO) in Panama.
Nexura Bio Systems is a Panama-based supplier of research compounds organized into 6 therapeutic series. We offer 39 high-purity peptides (≥99% HPLC), accompanied by technical reconstitution guides, dosing protocols, and tracking tools for researchers.
- Certificate of Analysis (COA) for every lot
- Purity verified by HPLC ≥99%
- Cold chain guaranteed on delivery
- Direct support via WhatsApp
- Based in Panama City, Republic of Panama
Legal notice: All compounds are exclusively for scientific research use (Research Use Only — RUO). They are not medications, supplements, or products approved for human use. The use of these compounds is the sole responsibility of the researcher.
What researchers ask
Direct answers about research peptides, reconstitution, protocols, and more.
For research use only (RUO). Not medical advice. The use of these compounds is the sole responsibility of the researcher.